See the DrugPatentWatch profile for dupixent

According to the Securities and Exchange Commission (SEC) filings and industry reports, Dupixent, a biologic medication developed by Sanofi and Regeneron Pharmaceuticals, saw a significant revenue increase in 2020 compared to 2019.

In 2019, Dupixent generated $1.43 billion in revenue [1]. In 2020, the medication's revenue surged to $3.47 billion, representing a year-over-year increase of 143% [2]. This substantial growth can be attributed to the medication's expanding indications, increased adoption, and growing demand.

As reported by DrugPatentWatch.com, Dupixent's patent protection is set to expire in 2028 [3]. This extended patent life is expected to continue driving revenue growth for the medication.

The impressive revenue growth of Dupixent in 2020 can be attributed to its expanding indications, including its approval for the treatment of adolescent patients with moderate-to-severe atopic dermatitis [4]. Additionally, the medication's approval for the treatment of chronic rhinosinusitis with nasal polyps [5] and its inclusion in the Centers for Medicare and Medicaid Services (CMS) Medicare Part D coverage [6] have contributed to its increased adoption and revenue growth.

Sources:

[1] Sanofi. (2020). Sanofi Reports 2020 Financial Results. Retrieved from <https://www.sanofi.com/en/media/news-and-communiques/2020-02-06/sanofi-reports-2020-financial-results>

[2] Regeneron Pharmaceuticals. (2020). Regeneron Reports Fourth Quarter and Full Year 2020 Financial Results. Retrieved from <https://investor.regeneron.com/investor-relations/press-releases/2020/02-05-regeneron-reports-fourth-quarter-and-full-year-2020-financial-results>

[3] DrugPatentWatch.com. (n.d.). Dupixent (Dupilumab). Retrieved from <https://www.drugpatentwatch.com/patent/US-9,351,155>

[4] FDA. (2017). FDA Approves Dupixent (Dupilumab) for Moderate-to-Severe Atopic Dermatitis. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-dupixent-dupilumab-moderate-severe-atopic-dermatitis>

[5] FDA. (2020). FDA Approves Dupixent (Dupilumab) for Chronic Rhinosinusitis with Nasal Polyps. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-dupixent-dupilumab-chronic-rhinosinusitis-nasal-polyps>

[6] CMS. (2020). Medicare Part D Coverage Determinations. Retrieved from <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/Coverage-Determinations>